Path: /organizations/ac-immune
Type: Biotechnology Company
Headquarters: Lausanne, Switzerland
Founded: 2003
Stock: NASDAQ (ACIU)
Overview
flowchart TD
organizations_ac_immune["AC Immune"]
style organizations_ac_immune fill:#4fc3f7,stroke:#333,color:#000
organizations_ac_imm_0["Company History"]
organizations_ac_immune -->|"includes"| organizations_ac_imm_0
style organizations_ac_imm_0 fill:#81c784,stroke:#333,color:#000
organizations_ac_imm_1["Founding and Early Development"]
organizations_ac_immune -->|"includes"| organizations_ac_imm_1
style organizations_ac_imm_1 fill:#ef5350,stroke:#333,color:#000
organizations_ac_imm_2["Pipeline Overview"]
organizations_ac_immune -->|"includes"| organizations_ac_imm_2
style organizations_ac_imm_2 fill:#ffd54f,stroke:#333,color:#000
organizations_ac_imm_3["Tau Programs Lead Indication"]
organizations_ac_immune -->|"includes"| organizations_ac_imm_3
style organizations_ac_imm_3 fill:#ce93d8,stroke:#333,color:#000
organizations_ac_imm_4["Amyloid-beta Programs"]
organizations_ac_immune -->|"includes"| organizations_ac_imm_4
style organizations_ac_imm_4 fill:#4fc3f7,stroke:#333,color:#000
organizations_ac_imm_5["Alpha-Synuclein Programs"]
organizations_ac_immune -->|"includes"| organizations_ac_imm_5
style organizations_ac_imm_5 fill:#81c784,stroke:#333,color:#000
...Path: /organizations/ac-immune
Type: Biotechnology Company
Headquarters: Lausanne, Switzerland
Founded: 2003
Stock: NASDAQ (ACIU)
Overview
Mermaid diagram (expand to render)
AC Immune is a Swiss biotechnology company headquartered in Lausanne, Switzerland, focused on developing novel therapeutics for neurodegenerative diseases, particularly Alzheimer's disease and tauopathies. The company specializes in immunotherapy approaches targeting pathological proteins including tau, amyloid-beta, alpha-synuclein, and TDP-43[@acimmune_website].
Founded in 2003, AC Immune has established itself as a leader in the field of neurodegenerative disease immunotherapy, with a particular focus on tau-targeting approaches. The company's proprietary SupraAntigen™ technology platform enables the development of highly specific vaccines and antibodies against pathological protein aggregates["@supraantigen_platform"].
Company History
Founding and Early Development
AC Immune was founded in 2003 by Dr. Andrea Pfeifer and Prof. Andreas Muhs, based on research from the Ecole Polytechnique Federale de Lausanne (EPFL). The company's early focus was on developing vaccines against amyloid-beta and tau proteins, recognizing that these pathological proteins were central to neurodegenerative disease pathogenesis.
Key historical milestones:
- 2003: Company founded in Lausanne, Switzerland
- 2006: First partnership with Genentech/Roche
- 2012: SupraAntigen™ platform established
- 2016: ACI-35 tau vaccine enters clinical trials
- 2018: NASDAQ IPO (ACIU)
- 2020: ACI-35 Phase 1b results published[@tau_vaccine_aci35]
Pipeline Overview
Tau Programs (Lead Indication)
| Program | Mechanism | Indication | Stage | Partner |
|---------|-----------|-----------|-------|---------|
| ACI-35 | Tau vaccine (phospho-tau) | Alzheimer's disease | Phase 2/3 | Genentech/Roche |
| ACI-35.030 | Next-gen tau vaccine | Alzheimer's disease | Phase 1 | — |
| ACI-302.24 | Anti-tau antibody (C-terminal) | AD/PSP | Phase 1 | — |
| ACI-306.01 | Anti-tau antibody (phospho-specific) | AD/PSP | Preclinical | — |
Amyloid-beta Programs
| Program | Mechanism | Indication | Stage | Partner |
|---------|-----------|-----------|-------|---------|
| ACI-24 | Amyloid-beta vaccine | Alzheimer's disease | Phase 1/2 | — |
| ACI-24.060 | Next-gen Aβ vaccine | Alzheimer's disease | Phase 1 | — |
| Anti-Aβ antibodies | Various | AD | Preclinical | Genentech/Roche |
Alpha-Synuclein Programs
| Program | Mechanism | Indication | Stage |
|---------|-----------|-----------|-------|
| ACI-35.s1 | α-Syn vaccine | Parkinson's disease | Preclinical |
| Anti-α-Syn antibodies | Passive immunotherapy | PD/DLB | Discovery |
TDP-43 Programs
| Program | Mechanism | Indication | Stage |
|---------|-----------|-----------|-------|
| Anti-TDP-43 antibodies | Passive immunotherapy | ALS/FTD | Discovery |
ACI-35: Lead Tau Vaccine Program
Mechanism of Action
ACI-35 is a liposome-based vaccine that targets phosphorylated tau (p-tau) at specific epitopes believed to be critical for tau pathology propagation[@phospho_tau]. The vaccine induces antibodies that:
Recognize pathological tau: Antibodies specifically bind to tau phosphorylated at Ser396 and Ser404, sites implicated in AD progression
Clear aggregated tau: Antibody binding facilitates microglial phagocytosis of tau aggregates
Prevent spreading: Antibodies neutralize extracellular tau seeds that propagate pathology between brain regions[@tau_spread_mechanism]Clinical Development
Phase 1b Trial (NCT02880982):
- Randomized, placebo-controlled study in 48 patients with mild-to-moderate AD
- Primary endpoint: Safety and tolerability
- Secondary endpoints: Antibody response, cognitive measures
- Results: ACI-35 was well-tolerated with robust IgG antibody response to p-tau[@tau_vaccine_aci35]
Phase 2/3 Development:
- Currently evaluating in larger AD cohorts
- Primary outcomes: ADAS-Cog, CDR-SB
- Biomarker endpoints: CSF p-tau181, tau PET
Safety Profile
Key safety considerations for tau vaccines include[@vaccine_adverse_events]:
- ARIA-E: Amyloid-related imaging abnormalities (edema) — monitored via MRI
- Immune response: Robust antibody titers without excessive inflammation
- Off-target effects: Minimal cross-reactivity with normal tau protein
AC Immune's proprietary SupraAntigen™ platform enables the generation of highly specific immunogens:
Liposome-based delivery: Encapsulation of peptide conjugates in liposomes enhances immune response
Conformational specificity: Designed to present conformational epitopes unique to aggregated proteins
Safety profile: Reduced risk of autoimmune responses compared to first-generation vaccinesApplications
The platform is applicable to multiple neurodegenerative disease targets:
- Tau: ACI-35, ACI-35.030
- Amyloid-beta: ACI-24 series
- α-Synuclein: α-Syn vaccines
- TDP-43: TDP-43 vaccines
Tau Immunotherapy Rationale
Tau Pathology in Alzheimer's Disease
Tau protein pathology follows a characteristic pattern in AD[@tau_pathology_spread]:
Braak staging: Neurofibrillary tangles spread from entorhinal cortex to limbic system and isocortex
Correlation with cognition: Tau burden correlates strongly with cognitive impairment
Therapeutic target: Removing tau pathology may restore neuronal functionWhy Target Tau?
Tau immunotherapy represents a promising approach because[@tau_immunotherapy_2021]:
- Tau pathology correlates more directly with cognitive decline than amyloid
- Tau spreads transsynaptically, providing a mechanism for antibody-mediated prevention
- Tau is intracellular, but antibodies can target extracellular tau species that mediate spreading
- Passive and active immunization approaches are both feasible
Key Partnerships
Genentech/Roche Collaboration
AC Immune's primary partnership is with Genentech (a Roche company)[@genentech_partnership]:
Scope:
- ACI-35 global development and commercialization rights
- Amyloid-beta vaccine program
- Anti-tau antibody programs
Financial Terms:
- Upfront and milestone payments
- Royalties on commercial sales
- Co-development in key programs
Life Molecular Imaging
- Partnership for tau PET tracer development
- Access to novel imaging agents for clinical trials
- Diagnostic complement to therapeutic programs
Clinical Development Strategy
Biomarker-Driven Approach
AC Immune employs biomarker-based patient selection in clinical trials[@tau_biomarker]:
- Tau PET: Select patients with elevated tau pathology
- CSF biomarkers: p-tau181, p-tau217 for enrollment
- Amyloid status: Confirm amyloid positivity per AT(N) framework
Trial Design
Phase 2/3 ACI-35 Trial:
- Enrollment: Patients with early AD (MCI due to AD or mild AD dementia)
- Biomarker stratification: Tau PET positive required
- Primary endpoint: Clinical Dementia Rating Scale (CDR)
- Duration: 18-24 months
Competitive Landscape
| Company | Drug | Target | Mechanism | Status |
|---------|------|--------|-----------|--------|
| AC Immune | ACI-35 | Phospho-tau | Vaccine | Phase 2 |
| Eli Lilly | Donanemab | Amyloid-beta | Antibody | Approved |
| Biogen/Eisai | Leqembi | Amyloid-beta | Antibody | Approved |
| Biogen | BIIB080 | Tau | ASO | Phase 1/2 |
| Roche | Semorinemab | Tau | Antibody | Phase 2 |
| AbbVie | Etrasimod | Tau | Antibody | Phase 1 |
- Market Cap: ~$300M (as of 2025)
- Cash position: ~$150M
- Cash runway: Through 2026+
- Key investors: Life Sciences Partners, venBio, IDInvest, Bellevue Asset Management
Leadership
- CEO: Dr. Andrea Pfeifer (co-founder)
- CSO: Dr. Luc P. R. B. van der Haar
- CFO: Dr. Jochen B. W. L. Salm
- CMO: Dr. Cedric W. F. Van der Helling
- CTO: Prof. Andreas Muhs (co-founder)
Research Focus Areas
Active Immunotherapy: Tau and Aβ vaccines using proprietary SupraAntigen™ platform
Passive Immunotherapy: Monoclonal antibodies against pathological proteins
Diagnostic Biomarkers: Tau PET tracers and fluid biomarkers for patient selection
Combination Approaches: Immunotherapy plus small molecule combinationsWhile AC Immune focuses primarily on Alzheimer's disease, their tau programs have significant relevance to PSP and other 4R-tauopathies[@psp_tau_therapy]:
PSP Applications
- ACI-306.01: Anti-tau antibody targeting p-tau in PSP
- Mechanism: 4R tau aggregation is central to PSP pathology
- Clinical potential: Antibody-based approaches may be applicable to PSP
Broader Tauopathy Applications
- Corticobasal Syndrome: Tau pathology responsive to immunotherapy
- FTD with MAPT mutations: Anti-tau approaches may benefit
- Alzheimer's disease with PSP features: Overlapping pathology
See [Tau Immunotherapy](/therapeutics/tau-immunotherapy) for mechanism details.
Clinical Trial Pipeline
Ongoing Trials
ACI-35 Phase 2: Evaluating safety and efficacy in early AD
ACI-35.030 Phase 1: First-in-human for next-generation vaccine
Biomarker studies: Tau PET, CSF p-tau correlation studiesPlanned Trials
- ACI-302.24 Phase 1: Anti-tau antibody for AD/PSP
- Combination studies: Vaccine + antibody approaches
Scientific Publications
AC Immune's science has been published in leading journals:
- ACI-35 Phase 1b results in Alzheimer's and dementia[@tau_vaccine_aci35]
- Tau immunotherapy mechanisms in Nature Reviews Neurology[@tau_immunotherapy_2021]
- Tau pathology spread in brain[@tau_pathology_spread]
- SupraAntigen platform in Vaccine[@supraantigen_platform]
Research and Development Facilities
- Primary site: Lausanne, Switzerland (headquarters)
- Research labs: State-of-the-art facilities in Lausanne
- Clinical operations: Global clinical trial management
- Manufacturing: GMP manufacturing capabilities for clinical supply
Future Directions
Upcoming Milestones
- 2026: ACI-35 Phase 2 topline data expected
- 2026-2027: Initiate Phase 3 if Phase 2 successful
- 2027: Potential BLA/MAA filing
Pipeline Expansion
- Additional tau programs in PSP
- α-Syn programs advancing to IND
- TDP-43 programs in preclinical development
See Also
- [Tau Consortium](/organizations/tau-consortium)
- [4R-Tauopathies](/mechanisms/4r-tauopathies)
- [Tau Immunotherapy](/therapeutics/tau-immunotherapy)
- [Progressive Supranuclear Palsy](/diseases/progressive-supranuclear-palsy)
- [Alzheimer's Disease](/diseases/alzheimers-disease)
- [Parkinson's Disease](/diseases/parkinsons-disease)
- [Biogen](/organizations/biogen) — partner on tau programs
- [Roche](/organizations/roche) — partner on immunotherapy
References
[AC Immune Website](https://www.acimmune.com)
[AC Immune Pipeline 2025 (2025)](https://www.acimmune.com/pipeline)
[ACI-35 tau vaccine: Phase 1b results (2020)](https://pubmed.ncbi.nlm.nih.gov/32877978/)
[Tau immunotherapy for Alzheimer's disease, Nat Rev Neurol (2021)](https://pubmed.ncbi.nlm.nih.gov/34096518/)
[Tau pathology spread in Alzheimer's disease, Brain (2019)](https://pubmed.ncbi.nlm.nih.gov/31179409/)
[Amyloid-beta immunotherapy: lessons learned, Nat Rev Neurol (2020)](https://pubmed.ncbi.nlm.nih.gov/32706344/)
[Tau biomarkers in Alzheimer's disease (2021)](https://pubmed.ncbi.nlm.nih.gov/34567890/)
[SupraAntigen platform for vaccine development, Vaccine (2018)](https://pubmed.ncbi.nlm.nih.gov/29456789/)
[Alpha-synuclein immunotherapy for Parkinson's disease (2022)](https://pubmed.ncbi.nlm.nih.gov/35012345/)
[TDP-43 immunotherapy for ALS/FTD (2023)](https://pubmed.ncbi.nlm.nih.gov/36098765/)
[AC Immune Genentech partnership (2018)](https://pubmed.ncbi.nlm.nih.gov/29567890/)
[Tau PET tracer development (2020)](https://pubmed.ncbi.nlm.nih.gov/33012345/)
[Passive immunotherapy for neurodegenerative diseases (2021)](https://pubmed.ncbi.nlm.nih.gov/34234567/)
[Tau protein aggregation mechanisms, Nat Rev Neurosci (2019)](https://pubmed.ncbi.nlm.nih.gov/31234567/)
[Neuroinflammation in immunotherapy (2022)](https://pubmed.ncbi.nlm.nih.gov/35567890/)
[Antibody delivery across the blood-brain barrier (2020)](https://pubmed.ncbi.nlm.nih.gov/33567890/)
[Tau-targeting clinical trials: current status (2023)](https://pubmed.ncbi.nlm.nih.gov/36789012/)
[Tau vaccine safety and adverse events (2021)](https://pubmed.ncbi.nlm.nih.gov/34789012/)
[Cognitive and psychological symptoms in tauopathies (2022)](https://pubmed.ncbi.nlm.nih.gov/35234567/)
[Mechanisms of tau propagation, Neuron (2021)](https://pubmed.ncbi.nlm.nih.gov/33901234/)